vs
Side-by-side financial comparison of Foghorn Therapeutics Inc. (FHTX) and Inuvo, Inc. (INUV). Click either name above to swap in a different company.
Inuvo, Inc. is the larger business by last-quarter revenue ($14.3M vs $9.2M, roughly 1.5× Foghorn Therapeutics Inc.). Inuvo, Inc. runs the higher net margin — -4.2% vs -234.3%, a 230.1% gap on every dollar of revenue. On growth, Foghorn Therapeutics Inc. posted the faster year-over-year revenue change (223.8% vs -45.6%). Over the past eight quarters, Foghorn Therapeutics Inc.'s revenue compounded faster (35.3% CAGR vs -8.5%).
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.
Inuvo, Inc. is a digital marketing technology firm that develops AI-powered advertising solutions. It offers intent-based audience targeting, performance marketing, and brand awareness services for retail, finance, and consumer goods clients, mainly operating across the North American market.
FHTX vs INUV — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.2M | $14.3M |
| Net Profit | $-21.7M | $-593.9K |
| Gross Margin | — | 66.4% |
| Operating Margin | -258.2% | -8.5% |
| Net Margin | -234.3% | -4.2% |
| Revenue YoY | 223.8% | -45.6% |
| Net Profit YoY | -11.1% | -520.2% |
| EPS (diluted) | $-0.35 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.2M | $14.3M | ||
| Q3 25 | $8.2M | $22.6M | ||
| Q2 25 | $7.6M | $22.7M | ||
| Q1 25 | $6.0M | $26.7M | ||
| Q4 24 | $2.9M | $26.2M | ||
| Q3 24 | $7.8M | $22.4M | ||
| Q2 24 | $6.9M | $18.2M | ||
| Q1 24 | $5.0M | $17.0M |
| Q4 25 | $-21.7M | $-593.9K | ||
| Q3 25 | $-15.8M | $-1.7M | ||
| Q2 25 | $-17.9M | $-1.5M | ||
| Q1 25 | $-18.8M | $-1.3M | ||
| Q4 24 | $-19.5M | $141.3K | ||
| Q3 24 | $-19.1M | $-2.0M | ||
| Q2 24 | $-23.0M | $-1.7M | ||
| Q1 24 | $-25.0M | $-2.1M |
| Q4 25 | — | 66.4% | ||
| Q3 25 | — | 73.4% | ||
| Q2 25 | — | 75.4% | ||
| Q1 25 | — | 79.0% | ||
| Q4 24 | — | 83.1% | ||
| Q3 24 | — | 88.4% | ||
| Q2 24 | — | 84.0% | ||
| Q1 24 | — | 87.7% |
| Q4 25 | -258.2% | -8.5% | ||
| Q3 25 | -226.9% | -7.4% | ||
| Q2 25 | -279.2% | -9.0% | ||
| Q1 25 | -385.0% | -6.6% | ||
| Q4 24 | -840.5% | 0.8% | ||
| Q3 24 | -305.5% | -8.7% | ||
| Q2 24 | -386.6% | -9.3% | ||
| Q1 24 | -558.3% | -12.3% |
| Q4 25 | -234.3% | -4.2% | ||
| Q3 25 | -194.4% | -7.7% | ||
| Q2 25 | -237.3% | -6.6% | ||
| Q1 25 | -316.4% | -4.7% | ||
| Q4 24 | -682.9% | 0.5% | ||
| Q3 24 | -244.9% | -9.1% | ||
| Q2 24 | -333.6% | -9.6% | ||
| Q1 24 | -495.4% | -12.4% |
| Q4 25 | $-0.35 | — | ||
| Q3 25 | $-0.25 | $-0.12 | ||
| Q2 25 | $-0.28 | — | ||
| Q1 25 | $-0.30 | $-0.01 | ||
| Q4 24 | $-0.23 | $0.14 | ||
| Q3 24 | $-0.31 | $-0.15 | ||
| Q2 24 | $-0.45 | $-0.01 | ||
| Q1 24 | $-0.59 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.9M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-108.5M | $10.0M |
| Total Assets | $198.1M | $24.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.9M | — | ||
| Q3 25 | $89.3M | — | ||
| Q2 25 | $72.6M | — | ||
| Q1 25 | $61.0M | — | ||
| Q4 24 | $55.5M | — | ||
| Q3 24 | $57.7M | — | ||
| Q2 24 | $138.9M | $2.0M | ||
| Q1 24 | $79.3M | $2.0M |
| Q4 25 | $-108.5M | $10.0M | ||
| Q3 25 | $-89.7M | $10.4M | ||
| Q2 25 | $-76.7M | $12.1M | ||
| Q1 25 | $-61.7M | $13.4M | ||
| Q4 24 | $-45.5M | $13.5M | ||
| Q3 24 | $-28.3M | $12.4M | ||
| Q2 24 | $-14.3M | $13.5M | ||
| Q1 24 | $-97.5M | $15.1M |
| Q4 25 | $198.1M | $24.9M | ||
| Q3 25 | $205.0M | $29.9M | ||
| Q2 25 | $226.2M | $28.7M | ||
| Q1 25 | $258.7M | $31.7M | ||
| Q4 24 | $284.0M | $32.2M | ||
| Q3 24 | $308.4M | $29.0M | ||
| Q2 24 | $328.6M | $28.5M | ||
| Q1 24 | $255.0M | $29.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-22.3M | $21.0K |
| Free Cash FlowOCF − Capex | — | $-339.9K |
| FCF MarginFCF / Revenue | — | -2.4% |
| Capex IntensityCapex / Revenue | 0.0% | 2.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-3.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-22.3M | $21.0K | ||
| Q3 25 | $-18.9M | $-1.6M | ||
| Q2 25 | $-21.0M | $143.7K | ||
| Q1 25 | $-24.0M | $-366.9K | ||
| Q4 24 | $-24.5M | $329.9K | ||
| Q3 24 | $-21.0M | $1.1M | ||
| Q2 24 | $-25.5M | $195.4K | ||
| Q1 24 | $-29.3M | $-1.4M |
| Q4 25 | — | $-339.9K | ||
| Q3 25 | — | $-2.0M | ||
| Q2 25 | $-21.0M | $-263.1K | ||
| Q1 25 | $-24.0M | $-818.6K | ||
| Q4 24 | $-25.0M | $-117.7K | ||
| Q3 24 | $-21.3M | $584.0K | ||
| Q2 24 | $-25.6M | $-266.3K | ||
| Q1 24 | $-29.4M | $-1.8M |
| Q4 25 | — | -2.4% | ||
| Q3 25 | — | -8.7% | ||
| Q2 25 | -278.2% | -1.2% | ||
| Q1 25 | -403.2% | -3.1% | ||
| Q4 24 | -875.3% | -0.4% | ||
| Q3 24 | -273.0% | 2.6% | ||
| Q2 24 | -371.0% | -1.5% | ||
| Q1 24 | -583.1% | -10.7% |
| Q4 25 | 0.0% | 2.5% | ||
| Q3 25 | 0.0% | 1.7% | ||
| Q2 25 | 0.3% | 1.8% | ||
| Q1 25 | 0.5% | 1.7% | ||
| Q4 24 | 16.8% | 1.7% | ||
| Q3 24 | 4.0% | 2.1% | ||
| Q2 24 | 0.2% | 2.5% | ||
| Q1 24 | 2.0% | 2.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 2.33× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
